Loading cancer entity…
Loading cancer entity…
Clinical trials
3,385 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01380106 | Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma | completed | Phase 2 | 33 | Boston VA Research Institute, Inc.OTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT00621244 | A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies | completed | Phase 1 / Phase 2 | 175 | Novartis PharmaceuticalsINDUSTRY | 3 | Jan 5, 2021 | clinicaltrials |
| NCT01930162 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant(UCBT) | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 5, 2021 | clinicaltrials |
| NCT01058434 | Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation | completed | Phase 2 | 43 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 19, 2020 | clinicaltrials |
| NCT00708292 | A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. | completed | Phase 1 / Phase 2 | 29 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 17, 2020 | clinicaltrials |
| NCT01302886 | Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma | completed | Phase 2 | 41 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 17, 2020 | clinicaltrials |
| NCT01337752 | Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 17, 2020 | clinicaltrials |
| NCT01045681 | Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma(BVD) | completed | Phase 2 | 75 | Intergroupe Francophone du MyelomeNETWORK | 1 | Dec 7, 2020 | clinicaltrials |
| NCT01426828 | Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant | completed | Phase 2 | 40 | University of PennsylvaniaOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT01155583 | Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 45 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT00966693 | Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 77 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT02477215 | Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 38 | Parameswaran HariOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02217163 | Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma | completed | Phase 2 | 30 | Singapore General HospitalOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT00821249 | A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 55 | PfizerINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02092922 | A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM) | completed | Phase 2 | 154 | PfizerINDUSTRY | 8 | Oct 19, 2020 | clinicaltrials |
| NCT02192775 | UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus | completed | Phase 2 | 2 | University of ArkansasOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02237261 | Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma(BPV) | completed | Phase 2 | 46 | University Hospital HeidelbergOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00469209 | Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients | completed | Phase 1 / Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT00075621 | Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis | completed | Phase 2 | 62 | Boston Medical CenterOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT01989325 | A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma | completed | Phase 2 | 77 | PfizerINDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT00309842 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | completed | Phase 2 | 213 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT01090921 | Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 50 | Boston VA Research Institute, Inc.OTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT00718419 | A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma | completed | Phase 2 | 56 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 3, 2020 | clinicaltrials |
| NCT00570180 | Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma | completed | Phase 2 | 36 | University Health Network, TorontoOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT01842308 | Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 50 | Mayo ClinicOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT01605032 | Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 19 | Albert Einstein College of MedicineOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01885897 | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | completed | Phase 1 / Phase 2 | 33 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT02219178 | Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 42 | Cancer Trials IrelandNETWORK | 1 | Jul 17, 2020 | clinicaltrials |
| NCT01858558 | Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma | completed | Phase 2 | 102 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 29, 2020 | clinicaltrials |
| NCT00903968 | Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 58 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT02003625 | Meloxicam vs Placebo for Mobilization | completed | Phase 2 | 31 | Massachusetts General HospitalOTHER | 1 | May 18, 2020 | clinicaltrials |
| NCT01237951 | High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma | completed | Phase 2 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02636010 | Pembrolizumab (MK-3475) in MM Patients With Residual Disease | completed | Phase 2 | 20 | PETHEMA FoundationOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT01660633 | Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation | completed | Phase 2 | 61 | Acrotech Biopharma Inc.INDUSTRY | 1 | Apr 21, 2020 | clinicaltrials |
| NCT01212952 | Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 50 | Mayo ClinicOTHER | 1 | Apr 17, 2020 | clinicaltrials |
| NCT01245673 | Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma | completed | Phase 2 | 28 | University of PennsylvaniaOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT02902965 | Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 74 | Pharmacyclics Switzerland GmbHINDUSTRY | 6 | Mar 16, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01478581 | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 92 | Pharmacyclics LLC.INDUSTRY | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02168101 | Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma | completed | Phase 2 | 9 | SCRI Development Innovations, LLCOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT01049945 | Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 70 | Mayo ClinicOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT00003954 | Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 2 | Feb 6, 2020 | clinicaltrials |
| NCT00068718 | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 31, 2020 | clinicaltrials |
| NCT00096161 | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant | completed | Phase 2 | 36 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 31, 2020 | clinicaltrials |
| NCT00789776 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | completed | Phase 1 / Phase 2 | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT00040846 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT01484275 | A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma | completed | Phase 2 | 85 | Janssen Research & Development, LLCINDUSTRY | 11 | Jan 27, 2020 | clinicaltrials |
| NCT00558675 | A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy | completed | Phase 1 / Phase 2 | 6 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00793572 | Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma | completed | Phase 2 | 32 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 22, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jan 25, 2021source: clinicaltrials